How to buy Mylan NV shares
Own Mylan NV shares in just a few minutes.
Mylan N.V is a drug manufacturers—specialty & generic business with stocks listed in the US. Mylan NV shares (MYL) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Mylan NV
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Mylan NV. Find the share by name or ticker symbol: MYL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mylan NV reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Mylan NV, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Mylan NV. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Mylan NV key stats
- Compare share trading platforms
- Is Mylan NV stock a buy or sell?
- Mylan NV performance over time
- Can I short Mylan NV shares?
- Is Mylan NV suitable for ethical investing?
- Are Mylan NV shares over-valued?
- Mylan NV's financials
- How volatile are Mylan NV shares?
- Does Mylan NV pay a dividend?
- Have Mylan NV shares ever split?
- Other common questions
Mylan NV share priceUse our graph to track the performance of MYL stocks over time.
Mylan NV shares at a glance
|52-week range||USD$12.75 - USD$23.11|
|50-day moving average||USD$15.8451|
|200-day moving average||USD$15.9852|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.524|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Mylan NV stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Mylan NV under- or over-valued?
Valuing Mylan NV stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mylan NV's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mylan NV's P/E ratio
Mylan NV's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Mylan NV shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Mylan NV's PEG ratio
Mylan NV's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Mylan NV's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Mylan NV's EBITDA
Mylan NV's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.5 billion.
The EBITDA is a measure of a Mylan NV's overall financial performance and is widely used to measure a its profitability.
Mylan NV financials
|Revenue TTM||US$11.5 billion|
|Operating margin TTM||15.22%|
|Gross profit TTM||US$4.6 billion|
|Return on assets TTM||3.53%|
|Return on equity TTM||2.29%|
|Market capitalisation||US$7.3 billion|
TTM: trailing 12 months
Shorting Mylan NV shares
There are currently 44.1 million Mylan NV shares held short by investors – that's known as Mylan NV's "short interest". This figure is 20.3% up from 36.7 million last month.
There are a few different ways that this level of interest in shorting Mylan NV shares can be evaluated.
Mylan NV's "short interest ratio" (SIR)
Mylan NV's "short interest ratio" (SIR) is the quantity of Mylan NV shares currently shorted divided by the average quantity of Mylan NV shares traded daily (recently around 4.6 million). Mylan NV's SIR currently stands at 9.58. In other words for every 100,000 Mylan NV shares traded daily on the market, roughly 9580 shares are currently held short.
However Mylan NV's short interest can also be evaluated against the total number of Mylan NV shares, or, against the total number of tradable Mylan NV shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mylan NV's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Mylan NV shares in existence, roughly 90 shares are currently held short) or 0.1096% of the tradable shares (for every 100,000 tradable Mylan NV shares, roughly 110 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Mylan NV.
Find out more about how you can short Mylan NV stock.
Mylan NV's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Mylan NV.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Mylan NV's total ESG risk score
Total ESG risk: 37.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Mylan NV's overall score of 37.23 (as at 07/31/2020) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Mylan NV is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Mylan NV's environmental score
Environmental score: 1.95/100
Mylan NV's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan NV is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Mylan NV's social score
Social score: 20.21/100
Mylan NV's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan NV is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Mylan NV's governance score
Governance score: 14.07/100
Mylan NV's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Mylan NV is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Mylan NV's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Mylan NV scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Mylan NV has a damaged public profile.
Environmental, social, and governance (ESG) summary
|Total ESG score||37.23|
|Total ESG percentile||77.54|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||4|
Mylan NV share dividends
We're not expecting Mylan NV to pay a dividend over the next 12 months.
Have Mylan NV's shares ever split?
Mylan NV's shares were split on a 3:2 basis on 8 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Mylan NV shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Mylan NV shares which in turn could have impacted Mylan NV's share price.
Mylan NV share price volatility
Over the last 12 months, Mylan NV's shares have ranged in value from as little as US$12.75 up to US$23.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mylan NV's is 1.505. This would suggest that Mylan NV's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mylan NV overview
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Frequently asked questions
Ask an Expert